OS Therapies Inc. OSTX 深 沪
已收盘 12-12 16:00:00 美东时间
1.81
-0.220
-10.84%
华盛通- 最 高1.99
- 今 开1.99
- 成交量 132.96万股
- 最 低 1.7045
- 昨 收 2.03
- 总市值 5727.75万
- 52周最高 7.00
- 市盈率 静 --
- 换手率 4.20%
- 52周最低 1.12
- 委 比 0.00%
- 总股本 3164.50万
- 历史最高 7.00
- 量 比 2.31
- 振 幅 14.06%
- 历史最低 1.12
- 每 手 1
- 风险率 0.80%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多OS Therapies Says U.S. FDA Grants Waiver Of Application Fee For BLA Filing Of OST-HER2; Type C Meeting With FDA Scheduled On December 11
U.S. FDA grants waiver of application fee for BLA Filing of OST-HER2Scheduled pre-Marketing Authorisation Application meeting with United Kingdom's Medicines and Healthcare products Regulatory Agency on December 8,
12-05 21:09
OS Therapies Announces WHO's INN Expert Committee Approves Daznelimgene Lisbac For Non-Proprietary Name For Company's HER2
OS Therapies Inc. (NYSE:OSTX) ("OS Therapies" or "the Company"), the world leader in listeria-based cancer immunotherapies, today announced that the International Nonproprietary Names (INN) Expert Committee of the World
11-25 22:27
美股大行评级 | Stifel上调英伟达目标价升至250美元；大摩上调哔哩哔哩目标价升至27美元；NICE遭多家机构下调目标价
今日重点评级关注：Oppenheimer：维持Olema Pharmaceuticals"跑赢大市"评级，目标价从22美元升至45美元；Bernstein：维持Atlassian"跑赢大市"评级，目标价从290美元升至304美元
11-19 11:01
美股大行评级 | Stifel上调特斯拉目标价升至508美元；多家大行上调Vita Coco目标价最高至58美元
今日重点评级关注：HC Wainwright & Co.：维持Oncolytics Biotech"买入"评级，目标价从5美元升至10美元；HC Wainwright & Co.：维持Barinthus Biotherapeutics"买入"评级，目标价从3美元升至4美元
11-18 15:28
D. Boral Capital Maintains Buy on OS Therapies, Maintains $20 Price Target
D. Boral Capital analyst Jason Kolbert maintains OS Therapies (AMEX:OSTX) with a Buy and maintains $20 price target.
11-17 21:17
OS Therapies Targets January 2026 BLA Filing for OST-HER2, Expects PRV Revenue in 2026
OS Therapies Inc. (NYSE:OSTX) ("OS Therapies" or "the Company"), the world leader in listeria-based cancer immunotherapies, today reported third quarter 2025 financial results for the period ended September 30, 2025 and
11-17 19:06
Why Quantum Computing Shares Are Trading Higher By Over 23%; Here Are 20 Stocks Moving Premarket
Shares of Quantum Computing Inc. (NASDAQ:QUBT) rose sharply in pre-market tradi...
11-17 17:42
OS Therapies Releases Investor Presentation for Stakeholders
OS Therapies Incorporated ( ($OSTX) ) just unveiled an announcement. On October...
10-18 05:28
OS Therapies Granted Second Type C Meeting From U.S. Food & Drug Administration For Biologics Licensing Application Of OST-HER2 To Treat Pulmonary Metastatic Osteosarcoma
Final FDA Type C Meeting December 11, 2025 - biomarker data to be availableOctober 10, 2025 FDA/Osteosarcoma Institute Workshop narrows focus for OST-HER2 overall survival, biomarker correlation & canine osteosarcoma
10-17 21:20
OS Therapies Announces Positive Regulatory Update Following October 6 Meeting With EMA Rapporteur, Dutch Medicines Evaluation Board
Overall survival recognized as key efficacy endpoint in osteosarcoma, where no standard of care existsRapporteur highlights potential broader benefits of OST-HER2 in pulmonary and primary osteosarcoma settings, supported
10-09 19:43
